Not long after the development of CRISPR-Cas9 gene editing in 2013, Vallabh and Minikel began thinking about whether CRISPR could be used to disrupt the gene encoding the prion protein.

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

Cystic fibrosis (CF) is a life-threatening genetic disease affecting multiple organ systems, with pancreatic dysfunction representing a critical and often overlooked complication.

Gene editing involves precise changes in DNA sequences using enzymes, revolutionizing medical, agricultural, and research ...

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...